US 7,459,527 B2
	BMP-7 variants with improved properties
John R. Desjarlais, Pasadena, Calif. (US); Shannon Alicia Marshall, San Francisco, Calif. (US); and Jonathan Zalevsky, Riverside, Calif. (US)
Assigned to Xencor, Inc., Monrovia, Calif. (US)
Filed on Mar. 31, 2005, as Appl. No. 11/97,960.
Claims priority of provisional application 60/558189, filed on Mar. 31, 2004.
Claims priority of provisional application 60/570520, filed on May 11, 2004.
Claims priority of provisional application 60/578432, filed on Jun. 09, 2004.
Claims priority of provisional application 60/587464, filed on Jul. 13, 2004.
Prior Publication US 2006/0058231 A1, Mar. 16, 2006
Int. Cl. C07K 14/00 (2006.01); C07K 14/52 (2006.01); C12N 15/00 (2006.01)

U.S. Cl. 530—350  [530/351; 435/69.1; 435/69.5]

2 Claims

1. A non-naturally occurring variant BMP-7 protein comprising amino acid D at position Vb(120) of the sequence: Fx(1-20)-Vb(21)-Fx(22-38)-Vb(39)-Fx(40-64)-Vb(65)-Fx(66-71)-Vb(72)-Fx(73-77)-Vb(78)-Fx(79-92)-Vb(93)-Fx(94-119)-Vb(120)-Fx(121-134)-Vb(135) whereinFx(1-20) corresponds to amino acid residues 1-20 of human BMP-7 (SEQ ID NO:5); Vb(21) is selected from the group consisting of L and G; Fx(22-38) corresponds to amino acid residues 22-38 of human BMP-7 (SEQ ID NO:5); Vb(39) is selected from the group consisting of K, A and S; Fx(40-64) corresponds to amino acid residues 40-64 of human BMP-7 (SEQ ID NO:5); Vb(65) is selected from the group consisting of Y and N; Fx(66-71) corresponds to amino acid residues 66-71 of human BMP-7 (SEQ ID NO:5); Vb(72) is selected from the group consisting of A and D; Fx(73-77) corresponds to amino acid residues 73-77 of human BMP-7 (SEQ ID NO:5); Vb(78) is selected from the group consisting of Y and H; Fx(79-92) corresponds to amino acid residues 79-92 of human BMP-7 (SEQ ID NO:5); Vb(93) is selected from the group consisting of F, H, S and T; Fx(94-119) corresponds to amino acid residues 94-119 of human BMP-7 (SEQ ID NO:5); Fx(121-134) corresponds to amino acid residues 121-134 of human BMP-7 (SEQ ID NO:5); Vb(135) is selected from the group consisting of A and E; wherein said variant comprises an amino acid substitution as compared to human BMP-7 (SEQ ID NO:5), wherein said variant retains at least 50% bioactivity relative to human BMP-7 (SEQ ID NO:5), as determined by differentiation of C2C12 cells as measured by alkaline phosphatase activity, and, wherein said variant BMP-7 protein differs from human BMP-7 (SEQ ID NO:5) by 1, 2, 3, 4 or 5 residues.